{"id":"NCT05146999","sponsor":"Galderma R&D","briefTitle":"Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines","officialTitle":"A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-09","primaryCompletion":"2022-10-28","completion":"2023-09-01","firstPosted":"2021-12-07","resultsPosted":"2024-10-21","lastUpdate":"2024-10-21"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Frown Lines"],"interventions":[{"type":"BIOLOGICAL","name":"QM1114-DP","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active arm - QM1114-DP","type":"ACTIVE_COMPARATOR"},{"label":"Inactive arm - Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines","primaryOutcome":{"measure":"Number of Responders Using the Global Aesthetic Improvement Scale (GAIS) at Month 1","timeFrame":"At Month 1","effectByArm":[{"arm":"Experimental: QM1114-DP","deltaMin":92,"sd":null},{"arm":"Placebo Comparator: Placebo","deltaMin":3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":99},"commonTop":["COVID-19","Upper respiratory tract infection","Headache","Basal cell carcinoma","Sinusitis"]}}